Dr. Francis Crick wrote in Nature, 1970, “The central dogma of molecular biology deals with the detailed residue-by-residue transfer of sequential information.” The overarching goal of Wang lab is to use variation in human genomics and phenomics to decode the residue-by-residue (and residue-to-residue) information flow through central dogma that shapes protein fold to drive function or dysfunction in the dynamic cellular context of human health and disease. We aim to develop both experimental and computational approaches to uncover the high-definition evolutionary trajectories for the form and function of the protein fold in the human population to enable an intelligent design of precision therapeutics.

Dr. Chao Wang has a long-standing interest and experience in studying protein homeostasis (proteostasis) in the cell and developing new therapeutic approaches for protein misfolding diseases. Major achievements in recent years include: (1) developed a new machine learning approach that uses a sparse collection of genetic variation in the human population to understand how each residue in the protein sequence contributes differentially to the complex mechanisms of disease or drug action. This approach helps identify new drug targets to guide precision disease management (Cell Reports2018; Structure 2022). (2) revealed how the acetylation-related epigenetic program and Hsp70 chaperone system impact the sequence, structure, and function relationships of a lysosomal protein to modulate cellular cholesterol homeostasis and rescue neurodegenerative disease (Nat. Commun.2019; Hum. Mol. Genet.2020). (3) used machine learning and pharmacological activators of unfolded protein response to correct a complex genetic disease with lung and liver disorders caused by protein misfolding and aggregation (Cell Chemical Biology2023). Dr. Chao Wang has received many rewards, including a travel award for the Lindau Nobel Laureate Meeting, the Ray Wu Prize, and fellowships from Alpha-1 Foundation and Cystic Fibrosis Research Foundation.

Sun, S.*, Wang, C.*, Zhao, P., Kline, G., Grandjean, J., Jiang, X., Labaudiniere, R., Wiseman, R.L., Kelly, J.W., and Balch, W.E. (2023) Capturing the Conversion of the Pathogenic Alpha-1-Antitrypsin Fold by ATF6 Enhanced Proteostasis. (*contributed equally). Cell Chemical Biology 30(1): 22-42. · Highlighted by preview in Cell Chemical Biology.

Wang, C.*, Angles, F.*, & Balch, W.E. (2022) Triangulating variation in the population to define mechanisms for precision management of genetic disease. Structure. 30(8): 1190-1207. (*contributed equally). · Highlighted in Genetic Engineering & Biotechnology News, Cystic Fibrosis News Today, ScienceDaily, Scripps News&Views etc. 

Wang, C.*, Zhao, P.*, Sun, S.*, Teckman, J., & Balch, W.E. (2020) Leveraging Population Genomics for Individualized Correction of the Hallmarks of Alpha-1-Antitrypsin Deficiency (AATD). Chronic Obstr Pulm Dis. 7(3): 224-246. (*contributed equally). 

Wang, C. *, Scott, S.M.*, Sun, S., Zhao, P., Hutt, D.M., Shao, H., Gestwicki, J.E., & Balch, W.E.  (2020) : Individualized Management of Genetic Diversity in Niemann-Pick C1 through Modulation of the Hsp70 Chaperone System. Hum. Mol. Genet. 29(1):1-19. (*contributed equally). 

Wang, C., Scott, S.M., Subramanian, K., Loguercio, S., Zhao, P., Hutt, D.M., Farhat, N.Y., Porter, F.D., & Balch W.E. (2019) Quantitating the epigenetic transformation contributing to cholesterol homeostasis using Gaussian process. Nat. Commun. 10(1):5052. 

Wang, C., Balch, W.E. (2018) Bridging Genomics to Phenomics at Atomic Resolution Using Variation Spatial Profiling. Cell Reports. 24(8): 2013-2028. · Cover Story. · Highlighted in Trends in Genetics.